Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-906 (Linsitinib) plus Paclitaxel in Ovarian Cancer and Solid Tumors
NCT00889382Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2009
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of linsitinib in ovarian epithelial cancer and solid tumor (8 arms), sponsored by Astellas Pharma. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 28 days and Progression Free Survival at 36 months. Started Aug 2009; status: completed.
02
Drugs
linsitinib
03
Conditions
ovarian epithelial cancersolid tumor
Beyond the preview
Go deeper on NCT00889382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00889382.